Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblastoma
Shots:
- The US FDA has granted RPD designation to alrizomadlin for the treatment of neuroblastoma
- The results showed that the therapy has a strong binding affinity to MDM2 & has the potential to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction. In earlier studies, APG-115 as monothx. shown antitumor activity in in vitro & in vivo models & showed an MoA supporting the clinical development of the product
- Alrizomadlin is a selective, small-molecule inhibitor of MDM2 protein & has received 6 ODDs, 1 FTD & 2 RPDs from the US FDA. The company plans to initiate the clinical study in neuroblastoma shortly to develop a new treatment option for pediatric patients
Ref: Cision PR Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
